

# Patent protection (1)

**Utility Patent** – "new and useful process, machine, manufacture or composition of matter"

20yrs



**Design Patent** – "new, original and ornamental design embodied in or applied to an article of manufacture"

14yrs

**Plant Patent** – "new and distinct, invented or discovered asexually reproduced plant"

# Patent protection (2)

**Utility Patent** – "new and useful process, machine, manufacture or composition of matter"

20yrs

**Design Patent** – "new, original and ornamental design embodied in or applied to an article of manufacture"

14yrs

**Plant Patent** – "new and distinct, invented or discovered asexually reproduced plant"





# Patent protection (3)


**Utility Patent** – "new and useful process, machine, manufacture or composition of matter"

20yrs

**Design Patent** – "new, original and ornamental design embodied in or applied to an article of manufacture"

14yrs

**Plant Patent** – "new and distinct, invented or discovered asexually reproduced plant"



## Patent protection (4)


**Utility Patent** – "new and useful process, machine, manufacture or composition of matter"

20yrs

**Design Patent** – "new, original and ornamental design embodied in or applied to an article of manufacture"

14yrs

**Plant Patent** — "new and distinct, invented or discovered asexually reproduced plant"





## **Patent protection - criteria**

- Novelty
- Usefulness
- Non-obvious
- Timing!



## **US** commercial development

- Public Heath Service PHS
- Food and Drug Administration FDA
- 6 Centers

#### **CDRH**

Center for Devices and Radiological Health

#### **CDER**

Center for Drug Evaluation and Research

#### **CBER**

Center for Biologics Evaluation and Research

Food Safety and Cosmetics Veterinary Medicine Toxicological Research Tissue Engineered Medical Products

(TEMPS)

## **US** commercial development (cont.)

**Public Heath Service – PHS** 

Food and Drug Administration – FDA

Safe Medical Device Act of 1990 Medical Device User Fee and Modernization Act of 2002 Office of Combination Products

Office of Orphan Products
Office of Regulatory Affairs

104

PUBLIC LAW 101-629—NOV. 28, 1990

Public Law 101–629 101st Congress

An Act

To amend the Federal Food, Drug, and Cosmetic Act to make improvements in the regulation of medical devices, and for other purposes.

## Regulatory process for combination product

### Request for Designation (RFD)

Primary Mode of Action (PMOA)

### **Device**

Investigational Device Exemption (IDE)

Institutional
Review Board
(IRB)
Phased Clinical
Trials

Pre-Market Approval (PMA) Predicate Device, Substantial Equivalence

Premarket Notification 510(k)

Clearance

Humanitarian
Use Device
(HUD)
<4,000 patients

Humanitarian
Device
Exemption
(HDE)


### **Biologic**

Investigational New Drug (IND)

Institutional
Review Board (IRB)
Phased Clinical Trials

Biologics License Approval (BLA)

## What comes after the market?



### **HCT/Ps** human cellular-and tissue-based products

- Current Good Tissue Practice for Human Cell, Tissues, and Cellular-and Tissue-Based Products (cGTP Rule)
- Task Force on Human Tissue Safety

### **Kick-down Criteria for 361 Products**

- 1. Minimal Manipulation of the source tissue (through processing)
- 2. Homologous use
- 3. Freedom from combination with another article (excluding sterilization, preservation or storage agents)
- 4. Absence of systemic effects or dependence on the metabolic activity of living cells (excluding autologous use, use in first degree relatives, or reproductive use)

### What does this all mean?

#### **FDA**

evaluates benefits/risks for the population

### Provider

evaluates benefits/risks for a patient

### **Patient**

evaluates benefits/risks in terms of personal values







